07:00 , Apr 16, 2012 |  BioCentury  |  Emerging Company Profile

Ceronco: Gateway into the cell

Ceronco BioSciences B.V. is developing a short chain sphingolipid delivery technology that preferentially increases the uptake of chemotherapeutics into cancer cells, which could improve efficacy without increasing toxicity. CEO Jeroen Rovers said many formulation technologies,...
07:00 , Apr 16, 2012 |  BC Week In Review  |  Clinical News

Ceronco Biosciences preclinical data

In a mouse model of breast cancer, CB001 significantly improved overall survival (OS) vs. controls (30 vs. 11 days, p<0.005). CB001 also significantly increased intracellular tumor accumulation of doxorubicin by 1.9-fold vs. doxorubicin alone (p<0.05)....
08:00 , Feb 12, 2007 |  BC Week In Review  |  Clinical News

CB001: Development discontinued

VIAC said it will discontinue development of CB001 after data from an open-label, U.S. Phase I/II trial in 10 patients showed no chimerism by days 21-28. VIAC said that chimerism, the presence of donor cells,...
07:00 , Jul 31, 2006 |  BC Week In Review  |  Clinical News

Hematopoietic stem cells: Preliminary Phase I/II data

Preliminary data from an open-label, U.S. Phase I/II trial in 10 patients showed no infusion toxicity events related to CB001. Patients will continue to be followed for 100 days post-transplant. FDA had lifted a clinical...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Clinical News

Hematopoietic stem cells: Phase I ongoing

FDA lifted its clinical hold on a Phase I trial. The trial was stopped after 2 cases of grade IV acute graft-versus-host disease (GVHD) were seen in 8 patients treated with CB001 (see BioCentury, Sept....
07:00 , Sep 26, 2005 |  BC Week In Review  |  Clinical News

Hematopoietic stem cells: Phase I suspended enrollment

VIAC suspended enrollment in a Phase I trial of CB001 for use in hematopoietic stem cell transplantation to treat cancer. The trial was stopped after 2 cases of grade IV acute graft-versus-host-disease (GVHD) were seen...
07:00 , Sep 26, 2005 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Sep 26, 2005 |  BioCentury  |  Finance

Ebb & Flow

Although...
23:53 , Sep 19, 2005 |  BC Extra  |  Clinical News

ViaCell falls on Phase I suspension

Cord blood company VIAC fell $1.39 (22%) to $5.05 on Monday on 2.6 million shares after it suspended enrollment in a Phase I trial of CB001 for use in hematopoietic stem cell transplantation to treat...
07:00 , May 16, 2005 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes...